Search

Charles River Laboratories International Inc

Nyitva

SzektorEgészségügy

272.7 -1.88

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

266.58

Maximum

279

Fő mutatók

By Trading Economics

Bevétel

14M

-760K

Értékesítés

8.2M

1B

Egy részvényre jutó nyereség

3.02

Profit margin

-0.076

Munkavállalók

18,300

EBITDA

87M

151M

Ajánlások

By TipRanks

Ajánlások

Erős vétel

12 hónapos előrejelzés

+2.94% upside

Osztalékok

By Acuity

Következő eredményjelentés

2026. nov. 4.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

2.6B

14B

Előző nyitás

274.58

Előző zárás

272.7

Hangulat hírek alapján

By Acuity

22%

78%

33 / 339 Rangsor szerint Healthcare

Charles River Laboratories International Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. szept. 10. 19:46 UTC

Charles River Laboratories is declining for a fourth consecutive session, influenced by macroeconomic factors and trading below its 20-day moving average.

2026. szept. 9. 23:36 UTC

Charles River Laboratories shares are trading slightly higher in after-market hours, despite remaining below their 20-day moving average after recent declines.

2026. szept. 8. 20:07 UTC

Charles River Laboratories International Inc shares declined during Tuesday's session, remaining near the lower end of their one-month trading range.

2026. szept. 4. 19:16 UTC

Shares of Charles River Laboratories International Inc. are lower today amid notable volatility and broader market concerns about potential Federal Reserve interest rate hikes.

2026. szept. 3. 23:01 UTC

Charles River Laboratories is higher in after-market trading, recovering from an initial dip and nearing the upper end of its one-month trading range.

2026. szept. 2. 22:02 UTC

Shares of Charles River Laboratories are lower in after-market trading following a volatile session. Broader market dynamics may be influencing the asset's movement.

2026. szept. 1. 22:06 UTC

Charles River Laboratories shares rose after-market, continuing to show resilience despite broader market pressure from rising bond yields and inflation expectations.

2026. aug. 31. 20:07 UTC

Charles River Laboratories is lower today amid broader market pressures from inflation concerns and potential interest rate hikes following the Jackson Hole Economic Symposium.

2026. aug. 28. 23:36 UTC

Charles River Laboratories is advancing in after-market trading, continuing its upward movement since Friday's close amid broader market dynamics. No specific news was identified.

2026. aug. 27. 22:01 UTC

Charles River Laboratories shares are higher in after-market hours, reflecting a positive trend despite earlier session volatility. Market factors remain under close observation.

2026. aug. 26. 19:16 UTC

Correlated Moves

Charles River Laboratories reports first-quarter revenue of $1.03 billion, missing estimates. Shares are lower amid sector declines and ongoing inflation concerns.

2026. aug. 25. 23:56 UTC

Charles River Laboratories shares are higher in after-market trading, maintaining a position near the upper end of their one-month range amid lower crude oil prices.

2026. aug. 24. 19:16 UTC

Correlated Moves

Charles River Laboratories is trading roughly flat amid a notable decline in Agilent Technologies. Market focus is on upcoming events, including a Federal Reserve speech.

2026. aug. 21. 23:01 UTC

Charles River Laboratories shares declined in after-market trading, amid broader market volatility tied to rising U.S. Treasury yields and inflation concerns.

2026. aug. 20. 19:41 UTC

News

Charles River Laboratories partners with Medigen to develop a multivalent enterovirus vaccine, supporting regulatory readiness and non-clinical studies. Shares are trading higher.

2026. aug. 19. 23:56 UTC

Charles River Laboratories shares are higher in after-market trading, reaching a notable increase since Wednesday's close and positioning near the upper end of its one-month range.

2026. aug. 17. 19:26 UTC

Charles River Laboratories shares are higher today, continuing an upward trend since Friday's close. The stock remains near the top of its one-month trading range.

2026. aug. 14. 19:46 UTC

Charles River Laboratories shares are lower amid broader market declines following a drop in U.S. retail sales, indicating potential weakening consumer demand.

2026. aug. 13. 19:52 UTC

Correlated Moves

Charles River Laboratories shares are lower today amid rising jobless claims and volatility, reflecting a decline since Wednesday's close.

2026. aug. 12. 20:51 UTC

Charles River Laboratories is higher in after-market trading, reflecting positive momentum despite no specific news. Broader market dynamics appear to support this resilience.

2026. aug. 11. 19:56 UTC

Charles River Laboratories International Inc. shares are trading higher today, maintaining a position above the 20-day moving average amid routine price movements.

2026. aug. 10. 19:16 UTC

News

Charles River Laboratories shares rise as TD Cowen and Mizuho raise price targets to $300 and $264, respectively. The stock shows notable strength since Friday.

2026. aug. 7. 19:51 UTC

News

Morgan Stanley raised its price target on Charles River Laboratories to $300, maintaining an Overweight rating as shares move higher since Thursday's close.

2026. aug. 6. 22:51 UTC

Shares of Charles River Laboratories International Inc. are lower in after-market trading, continuing a decline from Thursday's close despite being above its 20-day moving average.

2026. aug. 5. 23:56 UTC

Charles River Laboratories is higher in after-market hours, recovering from session lows. Broader market sentiment is affected by a disappointing ADP employment report.

2026. aug. 4. 19:16 UTC

Correlated Moves

Charles River Laboratories is rising amid positive momentum in the small-cap market, supported by a drop in crude oil prices that eases inflation concerns.

2026. aug. 3. 22:06 UTC

Charles River Laboratories shares are slightly higher in after-hours trading, supported by stronger-than-expected manufacturing data showing a rise in the PMI for July.

2026. júl. 31. 19:46 UTC

Correlated Moves

Charles River Laboratories reported first-quarter revenue of $1.02 billion and adjusted EPS of $2.06, but shares are lower amid broader market declines.

2026. júl. 30. 23:01 UTC

Shares of Charles River Laboratories are higher in after-market trading, reaching a peak above Thursday's close and remaining strong relative to recent trends.

2026. júl. 29. 19:18 UTC

Correlated Moves

Charles River Laboratories is lower today amid broader market declines and investor caution ahead of the Federal Reserve's monetary policy announcement.

Társak összehasonlítása

Árváltozás

Charles River Laboratories International Inc Előrejelzés

Célár

By TipRanks

2.94% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 286.455 USD  2.94%

Magas 320 USD

Alacsony 219 USD

12 Wall Street elemző 12 hónapos célárain alapulva a(z)Charles River Laboratories International Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

12 ratings

10

Vétel

2

Tartás

0

Eladás

Hangulat

By Acuity

33 / 339 Rangsor szerint Egészségügy

Hangulat hírek alapján

Nagyon erős bullish bizonyíték

Volatilitás

Átlag alatti

Hírmennyiség (RCV)

Átlag feletti

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat